Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01009944
Recruitment Status : Terminated (Not funded.)
First Posted : November 9, 2009
Last Update Posted : March 21, 2019
University of Utah
Information provided by (Responsible Party):
Gordon H. Williams, MD, Brigham and Women's Hospital

Brief Summary:
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Lisinopril, Atenolol Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Actual Study Start Date : January 2007
Actual Primary Completion Date : March 19, 2019
Actual Study Completion Date : March 19, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Lisinopril, Atenolol Drug: Lisinopril, Atenolol
once a day for 14 weeks
Other Names:
  • Tenormin (Atenolol)
  • Prinivil, Zestril (Lisinopril)

Primary Outcome Measures :
  1. One type of blood pressure medication will better treat individuals with certain genetic backgrounds. [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female hypertensive participants who were previously studied in SCOR program.

Exclusion Criteria:

  • Diabetes
  • Taking other medications beside thyroid or estrogen supplements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01009944

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
University of Utah
Layout table for investigator information
Principal Investigator: Gordon H. Williams, MD Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Gordon H. Williams, MD, Chief, Cardiovascular Endocrinology Section, Brigham and Women's Hospital Identifier: NCT01009944    
Other Study ID Numbers: 2007p002290
First Posted: November 9, 2009    Key Record Dates
Last Update Posted: March 21, 2019
Last Verified: March 2019
Keywords provided by Gordon H. Williams, MD, Brigham and Women's Hospital:
High blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents